Phathom Pharmaceuticals, Inc. Common Stock

Day range

$5.70 – $6.06

Open

$5.70

Prev close

$5.74

Volume

1.15M

Market cap

$464.37M

Shares out

80.9M

P/E

—

P/S

1.94

P/B

-1.35

P/FCF

—

ROE

28.8%

ROA

-30.3%

Debt/Equity

-0.48

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionOct 23, 2026

  Phathom believes that FDA carefully and correctly evaluated this issue in its June 6, 2025 grant of Phathom's December 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032.

• Annual meeting resultsMay 21, 2026

  On May 19, 2026, Phathom Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders. At the Annual Meeting, stockholders voted on the matters disclosed in the Company's definitive Proxy Statement. The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors, Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm, and Proposal No. 3 – Approval of the Compensation of the Named Executive Officers.

• Public offeringJan 8, 2026

  On January 7, 2026, Phathom Pharmaceuticals, Inc. entered into an underwriting agreement relating to the issuance and sale of (i) 6,875,000 shares of the Company's common stock at an offering price to the public of $16.00 per share, and (ii) pre-funded warrants to purchase an aggregate of 1,250,078 shares of Common Stock at a price of $15.999 per pre-funded warrant.

• Preliminary resultsJan 7, 2026

  On January 7, 2026, Phathom Pharmaceuticals, Inc. issued a press release announcing certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.

• Clinical trial resultsOct 27, 2025

  Results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (vonoprazan) tablets in patients with Non-Erosive Reflux Disease have been published in the American Journal of Gastroenterology. Key findings include percentage of heartburn-free nights, onset of effect, patient-reported outcomes, durability, and tolerability data from the trial.

Days to cover

7.4

Short interest

10.11M

Avg volume

1.37M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Phathom Pharmaceuticals Provides Update on FDA Litigation
  negativeGlobeNewswire Inc.· Oct 26, 2026
• Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
  negativeGlobeNewswire Inc.· Oct 23, 2026
• Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
  positiveGlobeNewswire Inc.· Sep 1, 2026
• Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
  positiveGlobeNewswire Inc.· May 1, 2026
• Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight
  positiveGlobeNewswire Inc.· Apr 13, 2026